Myofunctional therapy improves adherence to continuous positive airway pressure treatment

• Published in: Sleep & breathing Vol. 21; no. 2; pp. 387 - 395
• Main Authors: Diaféria, Giovana, Santos-Silva, Rogerio, Truksinas, Eveli, Haddad, Fernanda L. M., Santos, Renata, Bommarito, Silvana, Gregório, Luiz C., Tufik, Sergio, Bittencourt, Lia
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2017; Springer Nature B.V
• Subjects: Airway management; Continuous positive airway pressure; Dentistry; Internal Medicine; Medicine; Medicine & Public Health; Neurology; Otorhinolaryngology; Pediatrics; Pneumology/Respiratory System; Sleep apnea; Sleep Breathing Physiology and Disorders • Original Article; Therapy; Treatment; Polysomnography; Myofunctional therapy; Continuous positive airway pressure; Obstructive sleep apnea
• ISSN: 1520-9512; 1522-1709
• DOI: 10.1007/s11325-016-1429-6

Purpose Few studies have investigated myofunctional therapy in patients with obstructive sleep apnea syndrome (OSAS). The objective of this study was to evaluate the effect of myofunctional therapy on continuous positive airway pressure (CPAP) adherence. Methods The study was registered at ClinicalTrials.gov (NCT01289405). Male patients with OSAS were randomly divided into four treatment groups: placebo, patients undergoing placebo myofunctional therapy ( N  = 24); myofunctional therapy, undergoing myofunctional therapy ( N  = 27); CPAP, undergoing treatment with CPAP ( N  = 27); and combined, undergoing CPAP therapy and myofunctional therapy ( N  = 22). All patients underwent evaluations before and after 3 months of treatment evaluation and after 3 weeks of washout. Evaluations included Epworth sleepiness scale (ESS), polysomnography, and myofunctional evaluation. Results The 100 men had a mean age of 48.1 ± 11.2 years, body mass index of 27.4 ± 4.9 kg/m 2 , ESS score of 12.7 ± 3.0, and apnea-hypopnea index (AHI) of 30.9 ± 20.6. All treated groups (myofunctional therapy, CPAP, and combined myofunctional therapy with CPAP) showed decreased ESS and snoring, and the myofunctional therapy group maintained this improvement after the “washout” period. AHI reduction occurred in all treated groups and was more significant in CPAP group. The myofunctional therapy and combined groups showed improvement in tongue and soft palate muscle strength when compared with the placebo group. The association of myofunctional therapy to CPAP (combined group) showed an increased adherence to CPAP compared with the CPAP group. Conclusions Our results suggest that in patients with OSAS, myofunctional therapy may be considered as an adjuvant treatment and an intervention strategy to support adherence to CPAP.